Table 1.
Clinical and demographic characteristics of the study cohort (N = 123).
| Characteristics | Median | IQR |
|---|---|---|
| WBC (×103/L) | 8 | 3.5–30.0 |
| HGB (g/dL) | 9.1 | 8.5–10.0 |
| PLT (×103/μL) | 55 | 29–86 |
| BM blasts (%) | 46 | 30–67 |
| PB blasts (%) | 27 | 5–57 |
| LDH (U/L) | 689 | 478–1154 |
| Age (y) | 61 | 52–73 |
| No. | % | |
| Ontogeny | ||
| De novo | 93 | 76 |
| Secondary/therapy related | 30 | 24 |
| Prior treatment | ||
| Untreated | 88 | 72 |
| Treated | 35 | 28 |
| Karyotype | ||
| Normal karyotype | 91 | 74 |
| Complex karyotype | 12 | 10 |
| Others | 20 | 16 |
| Treatment | ||
| IA-based chemotherapy | 49 | 40 |
| AraC-based chemotherapy | 12 | 10 |
| decitabine and venetoclax | 27 | 22 |
| HMA without venetoclax | 24 | 20 |
| Others | 11 | 9 |
| Sex | ||
| Female | 48 | 39 |
Abbreviations: IQR interquartile range, WBC white blood cells, HGB hemoglobin, PLT platelets, BM bone marrow, PB peripheral blood, LDH lactate dehydrogenase, AML acute myeloid leukemia, IA idarubicin and cytarabine, AraC cytarabine, HMA hypomethylating agents.